Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19030481 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | January 2025 | June 2025 | Abandon | 5 | 1 | 0 | No | No |
| 18920212 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | October 2024 | March 2025 | Allow | 5 | 0 | 1 | No | No |
| 18314445 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | May 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18311708 | SALTS AND POLYMORPHS OF CERTAIN MCL-1 INHIBITORS | May 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18303226 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | April 2023 | November 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18187124 | DIHYDROCHROMENE DERIVATIVES | March 2023 | June 2025 | Allow | 27 | 0 | 1 | Yes | No |
| 18161678 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | January 2023 | May 2025 | Allow | 28 | 3 | 1 | Yes | No |
| 18068902 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18060053 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | November 2022 | March 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18052851 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | November 2022 | August 2024 | Allow | 22 | 1 | 0 | No | No |
| 17978469 | COMPOUNDS FOR METHODS FOR PROMOTING FEMALE REPRODUCTIVE HEALTH THROUGH MEDIATION OF RENIN ANGIOTENSIN FUNCTION | November 2022 | July 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18047960 | SOLID PHARMACEUTICAL TABLET | October 2022 | May 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17955425 | CANNABINOID-CONTAINING FORMULATIONS FOR PARKINSONIAN MOVEMENT DISORDERS | September 2022 | June 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17895443 | FENFLURAMINE FOR TREATMENT OF DEMYELINATING DISEASES AND CONDITIONS | August 2022 | May 2025 | Allow | 33 | 4 | 0 | No | No |
| 17716273 | BISDIAZABICYCLO COMPOUND FOR TREATING AND/OR PREVENTING HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS | April 2022 | October 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17620188 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives | December 2021 | May 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17619359 | NEW TRICYCLIC 5-HT2 ANTAGONISTS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17603961 | FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | October 2021 | November 2024 | Allow | 37 | 0 | 0 | No | No |
| 17602989 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | October 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17441085 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17447795 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17437780 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17310824 | MACROCYCLIC COMPOUNDS | August 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17310610 | FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR | August 2021 | May 2025 | Allow | 45 | 2 | 1 | No | No |
| 17402229 | PROSTATE FUNCTION SUPPORT FORMULA | August 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17430373 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | August 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17428090 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | August 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17428094 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17426804 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | July 2021 | March 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17424690 | NEW CRYSTALLINE FORMS OF A SUCCINATE SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDE | July 2021 | May 2025 | Allow | 45 | 2 | 0 | No | No |
| 17373006 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PULMONARY HYPERTENSION | July 2021 | June 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17421428 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17420335 | TOPICAL FORMULATIONS HAVING CANNABINOID | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17417983 | THIENOPYRIDINONE COMPOUNDS | June 2021 | May 2025 | Allow | 46 | 1 | 1 | No | No |
| 17414579 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17414655 | USE OF SULCONAZOLE AS A FURIN INHIBITOR | June 2021 | March 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17345557 | MUSCARINIC RECEPTOR AGONISTS | June 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17312669 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | June 2021 | October 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17311930 | DISUBSTITUTED ALKYNE DERIVATIVES | June 2021 | February 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17299760 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | June 2021 | December 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17298225 | CARBORANE-BASED HISTONE DEACETYLASE (HDAC) INHIBITORS | May 2021 | January 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17296460 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | May 2021 | April 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17296355 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17295497 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17325193 | Difluoro Phenyl Amide RIP1 Inhibitor | May 2021 | July 2024 | Allow | 38 | 2 | 0 | No | No |
| 17294225 | ERK INHIBITORS AND USES THEREOF | May 2021 | June 2025 | Allow | 49 | 1 | 1 | No | No |
| 17293255 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17292571 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | May 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17291994 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | May 2021 | April 2024 | Allow | 35 | 0 | 0 | No | No |
| 17290992 | COMPOSITION FOR INCREASING RETENTION OF CAROTENOID IN BLOOD | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17290257 | APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE | April 2021 | March 2025 | Allow | 47 | 3 | 0 | No | No |
| 17289125 | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) | April 2021 | July 2024 | Allow | 39 | 2 | 1 | No | No |
| 17238273 | MACROPINOCYTOSIS IN CANCER | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17286936 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | April 2021 | May 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17286967 | COMPOSITION FOR PREVENTING OR TREATING SJOGREN'S SYNDROME | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17285622 | QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND USES THEREOF | April 2021 | February 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17285776 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | April 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
| 17284149 | THYROID HORMONE RECEPTOR AGONISTS | April 2021 | April 2025 | Allow | 48 | 2 | 1 | No | No |
| 17280824 | TERPINOID DERIVATIVES AND USES THEREOF | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17204263 | POLYMYXIN-BASED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17187769 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | February 2021 | December 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17270201 | COMPOSITIONS AND METHODS RELATED TO CHOLIC ACID 7-SULFATE AS A TREATMENT FOR DIABETES | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17269830 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | February 2021 | September 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17269040 | SOLID STATE FORMS OF BRANAPLAM AND THEIR PREPARATION | February 2021 | May 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17268644 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | February 2021 | September 2023 | Allow | 31 | 0 | 0 | No | No |
| 17268151 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | February 2021 | March 2024 | Allow | 37 | 1 | 0 | No | No |
| 17263272 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | January 2021 | November 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17262341 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | January 2021 | March 2024 | Allow | 38 | 1 | 0 | No | No |
| 17055278 | INHIBITING MUTANT IDH-1 | November 2020 | April 2025 | Abandon | 53 | 2 | 0 | No | Yes |
| 17047383 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | October 2020 | April 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16987906 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | August 2020 | March 2025 | Allow | 55 | 5 | 0 | No | No |
| 16838684 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | April 2020 | March 2024 | Allow | 47 | 4 | 0 | Yes | Yes |
| 16725297 | PHOSPHODIESTERASE INHIBITOR TREATMENT | December 2019 | October 2024 | Allow | 58 | 4 | 1 | Yes | Yes |
| 16465137 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | May 2019 | January 2023 | Allow | 43 | 2 | 1 | Yes | Yes |
| 16461477 | SEXUAL HEALTH ENHANCEMENT COMPOSITION | May 2019 | March 2025 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHITE, DAWANNA SHAR-DAY.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHITE, DAWANNA SHAR-DAY works in Art Unit 1627 and has examined 73 patent applications in our dataset. With an allowance rate of 61.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner WHITE, DAWANNA SHAR-DAY's allowance rate of 61.6% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WHITE, DAWANNA SHAR-DAY receive 1.32 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WHITE, DAWANNA SHAR-DAY is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by WHITE, DAWANNA SHAR-DAY. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.1% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 46.2% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.